Study of JS004 Combined With Toripalimab for Advanced Lung Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 27, 2021

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2024

Conditions

Advanced Lung Cancer

Interventions

DRUG

JS004 in combination with toripalimab

Usage and dosage: 200mg of JS004 combined with 240mg of JS001 is given every 3 weeks

Trial Locations (2)

Cancer Hospital of Chinese Academy of Medical Sciences, Beijing

Jilin Cancer Hospital, Changchun

All Listed Sponsors

lead

Shanghai Junshi Bioscience Co., Ltd.

OTHER

NCT05000684 - Study of JS004 Combined With Toripalimab for Advanced Lung Cancer | Biotech Hunter | Biotech Hunter